Form 4: Tandem Diabetes Care Executive James Leal Reports Stock Transactions
SEC Form 4 Filing
James Leal, Chief Manufacturing Officer of Tandem Diabetes Care, reports the acquisition and disposal of company stock and restricted stock units.
Summary
- On May 28, 2024, James Leal, Chief Manufacturing Officer of Tandem Diabetes Care, reported transactions involving the company's stock.
- Leal acquired 310 shares of common stock upon the vesting of restricted stock units (RSUs).
- He also disposed of 129 shares to satisfy tax withholding requirements related to the RSU vesting at a price of $51.73 per share.
- Following these transactions, Leal directly owns 16,876 shares of Tandem Diabetes Care common stock.
- Additionally, Leal was awarded 16,257 restricted stock units on May 23, 2024, under the 2023 Long-Term Incentive Plan.
- These RSUs vest over time, with a portion vesting on May 15, 2025, and the remainder in equal quarterly installments.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Future Outlook
The awarded RSUs will continue to vest over time, potentially leading to further stock acquisitions by the reporting person.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- Vesting schedules for RSUs are typically structured to incentivize long-term performance and retention.
- Similar filings are regularly made by executives at comparable companies in the medical device industry, such as Insulet (PODD) and Dexcom (DXCM).
Stakeholder Impact
- Shareholders may be interested in tracking insider transactions as an indicator of management's confidence in the company.
- The transactions have a minimal direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of RSU award (16,257 units) under the 2023 Long-Term Incentive Plan |
| 05/28/2024 | Date of stock acquisition (310 shares) and disposal (129 shares for tax withholding) |
| 05/28/2024 | Date of Form 4 filing |
| 05/15/2025 | First vesting date for 33% of the RSUs awarded on May 23, 2024 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.